Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2017

  • ID: 4311856
  • Report
  • 110 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • BerGenBio ASA
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Ignyta Inc
  • Mirati Therapeutics Inc
  • MORE
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H1 2017

Summary:

According to the recently published report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017'; Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes.

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response.

The report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017' outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviewsalso reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 4, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Cardiovascular which include indications Non-Small Cell Lung Cancer, Solid Tumor, Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Gastric Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Refractory Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Head And Neck Cancer Squamous Cell Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Bone Metastasis, Colon Carcinoma, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Hematological Tumor, Kidney Cancer (Renal Cell Cancer), Leukemias, Liposarcoma, Liver Cancer, Melanoma, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Neuroendocrine Tumors, Non-Rhabdomyosarcoma, Ocular Melanoma, Pancreatic Ductal Adenocarcinoma, Papillary Renal Cell Carcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Skin Cancer, Thrombosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer and Wilms' Tumor (Nephroblastoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • BerGenBio ASA
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Ignyta Inc
  • Mirati Therapeutics Inc
  • MORE
  1. Introduction
  2. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Overview
  3. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
  14. Astellas Pharma Inc
  15. BerGenBio ASA
  16. Betta Pharmaceuticals Co Ltd
  17. Celldex Therapeutics Inc
  18. Exelixis Inc
  19. Ignyta Inc
  20. Les Laboratoires Servier SAS
  21. Mirati Therapeutics Inc
  22. Ono Pharmaceutical Co Ltd
  23. Oribase Pharma
  24. Qurient Co Ltd
  25. SignalChem Lifesciences Corp
  26. Takeda Pharmaceutical Company Ltd
  27. Tolero Pharmaceuticals Inc
  28. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
  29. Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile
  30. Product Description
  31. Mechanism Of Action
  32. R&D Progress
  33. BGB-002 - Drug Profile
  34. Product Description
  35. Mechanism Of Action
  36. R&D Progress
  37. BGB-324 - Drug Profile
  38. Product Description
  39. Mechanism Of Action
  40. R&D Progress
  41. BPI-9016 - Drug Profile
  42. Product Description
  43. Mechanism Of Action
  44. R&D Progress
  45. cabozantinib s-malate - Drug Profile
  46. Product Description
  47. Mechanism Of Action
  48. R&D Progress
  49. CT-053 - Drug Profile
  50. Product Description
  51. Mechanism Of Action
  52. R&D Progress
  53. CT-413 - Drug Profile
  54. Product Description
  55. Mechanism Of Action
  56. R&D Progress
  57. gilteritinib fumarate - Drug Profile
  58. Product Description
  59. Mechanism Of Action
  60. R&D Progress
  61. glesatinib - Drug Profile
  62. Product Description
  63. Mechanism Of Action
  64. R&D Progress
  65. HOPE-777 - Drug Profile
  66. Product Description
  67. Mechanism Of Action
  68. R&D Progress
  69. Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile
  70. Product Description
  71. Mechanism Of Action
  72. R&D Progress
  73. Monoclonal Antibody Conjugate to Inhibit AXL Kinase for Oncology - Drug Profile
  74. Product Description
  75. Mechanism Of Action
  76. R&D Progress
  77. ONO-7475 - Drug Profile
  78. Product Description
  79. Mechanism Of Action
  80. R&D Progress
  81. Q-701 - Drug Profile
  82. Product Description
  83. Mechanism Of Action
  84. R&D Progress
  85. Recombinant Protein to Inhibit Axl Tyrosine kinase for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
  86. Product Description
  87. Mechanism Of Action
  88. R&D Progress
  89. RXDX-106 - Drug Profile
  90. Product Description
  91. Mechanism Of Action
  92. R&D Progress
  93. S-49076 - Drug Profile
  94. Product Description
  95. Mechanism Of Action
  96. R&D Progress
  97. SGI-7079 - Drug Profile
  98. Product Description
  99. Mechanism Of Action
  100. R&D Progress
  101. sitravatinib - Drug Profile
  102. Product Description
  103. Mechanism Of Action
  104. R&D Progress
  105. SLC-0211 - Drug Profile
  106. Product Description
  107. Mechanism Of Action
  108. R&D Progress
  109. Small Molecule to Inhibit AXL for Oncology - Drug Profile
  110. Product Description
  111. Mechanism Of Action
  112. R&D Progress
  113. Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile
  114. Product Description
  115. Mechanism Of Action
  116. R&D Progress
  117. Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile
  118. Product Description
  119. Mechanism Of Action
  120. R&D Progress
  121. TP-0903 - Drug Profile
  122. Product Description
  123. Mechanism Of Action
  124. R&D Progress
  125. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Products
  126. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
  127. Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Product Development Milestones
  128. Featured News & Press Releases
  129. May 22, 2017: BerGenBio Announces Start of Randomized Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma
  130. May 19, 2017: Abstract showing activity in MDS of BerGenBio’s first-in-class AXL inhibitor, BGB324, accepted for presentation at ASCO Annual Meeting
  131. Apr 04, 2017: Ignyta Announces New Data Highlighting Broad Potential of RXDX-106 at the 2017 AACR Annual Meeting
  132. Mar 28, 2017: Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting
  133. Mar 06, 2017: Exelixis' Cabozantinib Granted Orphan Drug Designation for the Treatment of Hepatocellular Carcinoma
  134. Feb 17, 2017: Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
  135. Jan 09, 2017: BerGenBio To Present At 9th Annual Biotech Showcase
  136. Jan 05, 2017: Mirati Therapeutics Provides Update On Glesatinib Clinical Trial And Pipeline Program
  137. Jan 05, 2017: Mirati Therapeutics Provides Update On Sitravatinib Clinical Trial And Pipeline Program
  138. Dec 08, 2016: New Breast Cancer Research Highlights BGB324 In Overcoming Immunotherapy Resistance
  139. Dec 07, 2016: Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline
  140. Dec 05, 2016: BerGenBio Presents Promising Phase I Clinical & Biomarker Data From First In Class Axl Inhibitor BGB324 In AML at ASH
  141. Nov 29, 2016: BerGenBio Reports Promising BGB324 Phase I/II Monotherapy Data in Patients with Lung Cancer at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
  142. Nov 29, 2016: Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
  143. Nov 17, 2016: Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
  144. Appendix
  145. Methodology
  146. Coverage
  147. Secondary Research
  148. Primary Research
  149. Expert Panel Validation
  150. Contact Us
  151. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Indications, H1 2017 (Contd..2), H1
  6. Number of Products under Development by Companies, H1
  7. Products under Development by Companies, H1
  8. Products under Development by Companies, H1 2017 (Contd..1), H1
  9. Products under Development by Companies, H1 2017 (Contd..2), H1
  10. Products under Development by Companies, H1 2017 (Contd..3), H1
  11. Products under Development by Companies, H1 2017 (Contd..4), H1
  12. Products under Development by Companies, H1 2017 (Contd..5), H1
  13. Number of Products under Investigation by Universities/Institutes, H1
  14. Products under Investigation by Universities/Institutes, H1
  15. Number of Products by Stage and Mechanism of Actions, H1
  16. Number of Products by Stage and Route of Administration, H1
  17. Number of Products by Stage and Molecule Type, H1
  18. Pipeline by Astellas Pharma Inc, H1
  19. Pipeline by BerGenBio ASA, H1
  20. Pipeline by Betta Pharmaceuticals Co Ltd, H1
  21. Pipeline by Celldex Therapeutics Inc, H1
  22. ipeline by Exelixis Inc, H1
  23. Pipeline by Ignyta Inc, H1
  24. Pipeline by Les Laboratoires Servier SAS, H1
  25. Pipeline by Mirati Therapeutics Inc, H1
  26. Pipeline by Ono Pharmaceutical Co Ltd, H1
  27. Pipeline by Oribase Pharma, H1
  28. Pipeline by Qurient Co Ltd, H1
  29. Pipeline by SignalChem Lifesciences Corp, H1
  30. Pipeline by Takeda Pharmaceutical Company Ltd, H1
  31. Pipeline by Tolero Pharmaceuticals Inc, H1
  32. Dormant Products, H1
  33. Dormant Products, H1 2017 (Contd..1), H1
  34. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Stage and Routes of Administration, H1
  6. Number of Products by Molecule Types, H1
  7. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • BerGenBio ASA
  • Betta Pharmaceuticals Co Ltd
  • Celldex Therapeutics Inc
  • Exelixis Inc
  • Ignyta Inc
  • Les Laboratoires Servier SAS
  • Mirati Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • Oribase Pharma
  • Qurient Co Ltd
  • SignalChem Lifesciences Corp
  • Takeda Pharmaceutical Company Ltd
  • Tolero Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll